Amphastar reported third-quarter 2026 net revenues of $207.6 million, up 8% from $191.8 million a year earlier. GAAP net income was $37.8 million, or $0.87 per diluted share, compared with $17.4 million, or $0.37, in the prior-year quarter, which included a $23.1 million litigation provision. Gross margin fell to 48.0% from 51.4%, and the board authorized a $50 million increase to the share buyback program.
Net revenues $207.6 million vs $191.8 million in Q3 2025, up 8%
GAAP diluted EPS $0.87 vs $0.37; adjusted non-GAAP diluted EPS $1.14 vs $0.93
Gross margin 48.0% vs 51.4%, mainly from lower average selling prices and higher remediation-related manufacturing costs
Board authorized a $50 million increase to the share buyback program on November 4, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Amphstar Pharmaceuticals, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$719.89M
-1.7%
$2.03
-33.7%
13.6%
FY2024
$731.97M
+13.6%
$3.06
+17.7%
21.8%
FY2023
$644.39M
+29.1%
$2.60
+49.4%
21.3%
FY2022
$498.99M
+14.0%
$1.74
+39.2%
18.3%
FY2021
$437.77M
+25.1%
$1.25
+4066.7%
14.2%
Frequently asked questions
When is Amphstar Pharmaceuticals's next earnings date?
Amphstar Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Amphstar Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, Amphstar Pharmaceuticals reported diluted EPS of $0.87 (+135.1% year over year) on revenue of $207.61M (+8.2%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.